Skip to main content
SpringerLink
Log in

TH-302 – ein neues unter Hypoxie aktiviertes Zytostatikum beim Pankreaskarzinom

TH-302: a new hypoxia-activated cytostatic agent in pancreatic cancer treatment

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bentzen J, Toustrup K, Eriksen JG et al (2015) Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazoleand weekly cisplatin. Results from the DAHANCA 18 phase II study. Acta Oncol 1:1–7

    Google Scholar 

  2. Borad MJ, Reddy SG, Bahari N et al (2015) Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 33:1475–1487

    Article  CAS  PubMed  Google Scholar 

  3. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825

  4. http://en.wikipedia.org/wiki/Evofosfamide. Zugegriffen: 22. Apr. 2015

  5. Kuhnt T, Mueller AC, Pelz T et al (2005) Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy. J Cancer Res Clin Oncol 131:758–764

    Article  CAS  PubMed  Google Scholar 

  6. Overgaard J (2011) Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck – a systematic review and meta-analysis. Radiother Oncol 100:22–32

    Article  PubMed  Google Scholar 

  7. Overgaard J (1994) Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 6:509–518

    CAS  PubMed  Google Scholar 

  8. Overgaard J, Hansen HS, Overgaard M et al (1998) A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5–85. Radiother Oncol 46:135–146

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Strahlentherapie, UKSH Kiel, Arnold-Heller-Str. 3, 24105, Kiel, Deutschland

    Claudia Schmalz &  Jürgen Dunst

Authors
  1. Claudia Schmalz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jürgen Dunst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jürgen Dunst.

Additional information

Originalpublikation

Borad MJ, Reddy SG, Bahari N et al (2015) Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 33:1475–1483

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schmalz, C., Dunst, J. TH-302 – ein neues unter Hypoxie aktiviertes Zytostatikum beim Pankreaskarzinom. Strahlenther Onkol 191, 819–820 (2015). https://doi.org/10.1007/s00066-015-0877-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-015-0877-4

Search

Navigation